This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic germ cell cancer (GCC) who have failed initial BEP (bleomycin, etoposide and cisplatin) chemotherapy. Patients with first relapse following BEP for metastatic GCC, confirmed by biopsy or sequentially rising markers, received four courses of TIP (paclitaxel 175 mg m?² day 1, followed on days 1-5 by ifosfamide 1 g m?² intravenously (i.v.) and cisplatin 20 mg² i.v.) at 3-weekly intervals. The primary outcome measure was response to TIP. In all, 51 patients were registered, of whom 43 were eligible for response assessment. Eight achieved complete remission (CR) and 18 a partial remission with negative markers ...
Purpose: This prospective randomized multicenter trial was designed to evaluate the efficacy of carb...
Background: This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerabil...
BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high ...
The efficacy of paclitaxel was evaluated in combination with ifosfamide and cisplatin as second-line...
Purpose: To prospectively determine the efficacy of repeated high-dose alkylating chemotherapy to sa...
International audienceBACKGROUND: The standard treatment of patients with metastatic germ-cell tumor...
Purpose: To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T...
Background: To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfami...
The purpose of this study was to determine the activity of paclitaxel as a second-line chemotherapy ...
© The Author(s) 2014. This article is published with open access at Springerlink.com TIP as consolid...
BACKGROUND: We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatme...
Purpose: To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T...
AbstractBackgroundStandard chemotherapy for poor-prognosis metastatic nonseminoma has remained bleom...
Over the past two decades, the use of well-validated, guideline-based strategies resulted in high cu...
Background: This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerabil...
Purpose: This prospective randomized multicenter trial was designed to evaluate the efficacy of carb...
Background: This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerabil...
BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high ...
The efficacy of paclitaxel was evaluated in combination with ifosfamide and cisplatin as second-line...
Purpose: To prospectively determine the efficacy of repeated high-dose alkylating chemotherapy to sa...
International audienceBACKGROUND: The standard treatment of patients with metastatic germ-cell tumor...
Purpose: To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T...
Background: To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfami...
The purpose of this study was to determine the activity of paclitaxel as a second-line chemotherapy ...
© The Author(s) 2014. This article is published with open access at Springerlink.com TIP as consolid...
BACKGROUND: We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatme...
Purpose: To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T...
AbstractBackgroundStandard chemotherapy for poor-prognosis metastatic nonseminoma has remained bleom...
Over the past two decades, the use of well-validated, guideline-based strategies resulted in high cu...
Background: This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerabil...
Purpose: This prospective randomized multicenter trial was designed to evaluate the efficacy of carb...
Background: This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerabil...
BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high ...